Soluble Vascular Endothelial Growth Factor Receptor-2 and Inflammatory Factors in Macular Edema with Branch Retinal Vein Occlusion

被引:43
|
作者
Noma, Hidetaka [1 ]
Funatsu, Hideharu [1 ]
Mimura, Tatsuya [2 ]
Eguchi, Shuichiro [3 ]
Hori, Sadao [4 ]
机构
[1] Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Ophthalmol, Chiba 2768524, Japan
[2] Univ Tokyo, Dept Ophthalmol, Grad Sch Med, Tokyo 113, Japan
[3] Eguchi Eye Hosp, Dept Ophthalmol, Hakodate, Hokkaido, Japan
[4] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan
关键词
NF-KAPPA-B; INTRAVITREAL BEVACIZUMAB; VITREOUS LEVELS; LASER TREATMENT; ACTIVATION; EXPRESSION; INHIBITOR; CYTOKINES; VEGFR-2; PHOSPHORYLATION;
D O I
10.1016/j.ajo.2011.04.006
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To investigate relationships among vitreous fluid levels of soluble vascular endothelial growth factor receptor-2 (sVEGFR-2), vascular endothelial growth factor (VEGF), and soluble intercellular adhesion molecule 1 (sICAM-1) in patients with branch retinal vein occlusion (BRVO) and macular edema or patients with idiopathic macular hole. DESIGN: Retrospective case-control study. METHODS: SETTING: Tokyo Women's Medical University and Eguchi Eye Hospital. PATIENT POPULATION: Forty-nine Japanese patients who underwent unilateral vitrectomy (27 with BRVO and 22 with macular hole). OBSERVATION PROCEDURES: Vitreous fluid samples were obtained during vitreoretinal surgery to measure the levels of sVEGFR-2, VEGF, and sICAM-1. Retinal ischemia was evaluated from capillary nonperfusion on fluorescein angiography. Macular edema was examined by optical coherence tomography. MAIN OUTCOME MEASURES: Vitreous fluid levels of the 3 molecules and severity of macular edema. RESULTS: BRVO patients had a significantly higher vitreous fluid level of sVEGFR-2 (median, 1670 pg/mL; interquartile range [IQL], 1205 to 2225 pg/mL) than macular hole patients (median, 1265 pg/mL; IQR, 731 to 1800 pg/mL; P = .017), as was the case for VEGF (median, 237 pg/mL; IQR, 42.2 to 1305 pg/mL; vs median, 15.6 pg/mL; IQR, 15.6 to 15.6 pg/mL; P < .001) and sICAM-1 (median, 10.1 ng/mL; IQR, 6.3 to 22.5 ng/mL; vs median, 4.1 ng/mL; IQR, 3.3 to 6.0 ng/mL; P < .001). In BRVO patients, there was a significant positive correlation between vitreous fluid levels of sVEGFR-2 or VEGF and sICAM-1, but not between sVEGFR-2 and VEGF. Vitreous fluid levels of all 3 molecules were correlated significantly the with severity of macular edema in BRVO patients. CONCLUSIONS: sVEGFR-2 may induce an increase of vascular permeability together with or via sICAM-1, or both with and via sICAM-1, in BRVO patients with macular edema. (Am J Ophthalmol 2011;152:669-677. (C) 2011 by Elsevier Inc. All rights reserved.)
引用
收藏
页码:669 / 677
页数:9
相关论文
共 50 条
  • [21] Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion
    Shalchi, Zaid
    Mahroo, Omar
    Bunce, Catey
    Mitry, Danny
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (07):
  • [22] MACULAR EDEMA AND RETINAL BRANCH VEIN OCCLUSION
    GREER, DV
    CONSTABLE, IJ
    COOPER, RL
    AUSTRALIAN JOURNAL OF OPHTHALMOLOGY, 1980, 8 (03): : 207 - 209
  • [23] Aqueous Humor Levels of Soluble Vascular Endothelial Growth Factor Receptor and Inflammatory Factors in Diabetic Macular Edema
    Noma, Hidetaka
    Mimura, Tatsuya
    Yasuda, Kanako
    Motohashi, Ryosuke
    Kotake, Osamu
    Shimura, Masahiko
    OPHTHALMOLOGICA, 2017, 238 (1-2) : 81 - 88
  • [24] Predicting recurrences of macular edema due to branch retinal vein occlusion during anti-vascular endothelial growth factor therapy
    Misa Suzuki
    Norihiro Nagai
    Sakiko Minami
    Toshihide Kurihara
    Mamoru Kamoshita
    Hideki Sonobe
    Kazuhiro Watanabe
    Hajime Shinoda
    Kazuo Tsubota
    Yoko Ozawa
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258 : 49 - 56
  • [25] Predicting recurrences of macular edema due to branch retinal vein occlusion during anti-vascular endothelial growth factor therapy
    Suzuki, Misa
    Nagai, Norihiro
    Minami, Sakiko
    Kurihara, Toshihide
    Kamoshita, Mamoru
    Sonobe, Hideki
    Watanabe, Kazuhiro
    Shinoda, Hajime
    Tsubota, Kazuo
    Ozawa, Yoko
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 258 (01) : 49 - 56
  • [26] Anti-Vascular Endothelial Growth Factor Therapy with or Without Initial Steroid Therapy for Macular Edema in Branch Retinal Vein Occlusion
    Noma, Hidetaka
    Yasuda, Kanako
    Nonaka, Ryota
    Sasaki, Shotaro
    Shimura, Masahiko
    CLINICAL OPHTHALMOLOGY, 2023, 17 : 2267 - 2275
  • [27] Inflammatory Factors in Major and Macular Branch Retinal Vein Occlusion
    Noma, Hidetaka
    Funatsu, Hideharu
    Mimura, Tatsuya
    Eguchi, Shuichiro
    Shimada, Katsunori
    OPHTHALMOLOGICA, 2012, 227 (03) : 146 - 152
  • [28] Association of dilated capillary area and anti-vascular endothelial growth factor treatment requirement for macular edema in branch retinal vein occlusion
    Tsuboi, Kotaro
    Guo, Yukun
    Wang, Jie
    Kamei, Motohiro
    Hwang, Thomas
    Huang, David
    Jia, Yali
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (09)
  • [29] Effect of vitreomacular adhesion on antivascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion
    Ryo Terao
    Kentaro Yuda
    Kayo Kure
    Tatsuya Inoue
    Hiroshi Ohtsu
    Yasuo Yanagi
    Japanese Journal of Ophthalmology, 2014, 58 : 139 - 145
  • [30] Effect of vitreomacular adhesion on antivascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion
    Terao, Ryo
    Yuda, Kentaro
    Kure, Kayo
    Inoue, Tatsuya
    Ohtsu, Hiroshi
    Yanagi, Yasuo
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2014, 58 (02) : 139 - 145